Factors associated with suicidal ideation among people with HIV engaged in care.

HIV Polysubstance use Primary care screening Stimulants Suicide

Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
07 May 2024
Historique:
received: 16 12 2023
revised: 29 04 2024
accepted: 06 05 2024
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 9 5 2024
Statut: aheadofprint

Résumé

People with HIV (PWH) are at elevated risk for suicidal ideation (SI), yet few studies have examined how substance use, clinical and sociodemographic factors are associated with SI among PWH. We used substance use (Tobacco, Alcohol, Prescription Medication, and Other Substance Use [TAPS]) and depression (PHQ-9) data from computerized screening of adult PWH in primary care clinics in Northern California, combined with health record data on psychiatric diagnoses, HIV diagnosis, treatment, and control (HIV RNA, CD4), insurance, and neighborhood deprivation index (NDI) to examine factors associated with SI (PHQ-9 item 9 score > 0). Adjusted odds ratios (aOR) for SI were obtained from logistic regression models. Among 2829 PWH screened (92 % male; 56 % white; mean (SD) age of 54 (13) years; 220 (8 %) reported SI. Compared with no problematic use, SI was higher among those reporting one (aOR = 1.65, 95 % CI = 1.17, 2.33), two (aOR = 2.23, 95 % CI = 1.42, 3.49), or ≥ 3 substances (aOR = 4.49, 95 % CI = 2.41, 8.39). SI risk was higher for those with stimulant use (aOR = 3.55, 95 % CI = 2.25, 5.59), depression (aOR = 4.18, 95 % CI = 3.04, 5.74), and anxiety diagnoses (aOR = 1.67, 95 % CI = 1.19, 2.34), or Medicaid (aOR = 2.11, 95%CI = 1.24, 3.60) compared with commercial/other insurance. SI was not associated with HIV-related measures or NDI. SI was assessed with a single PHQ-9 item. Simultaneous SI and exposure data collection restricts the ability to establish substance use as a risk factor. HIV care providers should consider multiple substance use, stimulant use, depression or anxiety, and public insurance as risk factors for SI and provide interventions when needed.

Sections du résumé

BACKGROUND BACKGROUND
People with HIV (PWH) are at elevated risk for suicidal ideation (SI), yet few studies have examined how substance use, clinical and sociodemographic factors are associated with SI among PWH.
METHOD METHODS
We used substance use (Tobacco, Alcohol, Prescription Medication, and Other Substance Use [TAPS]) and depression (PHQ-9) data from computerized screening of adult PWH in primary care clinics in Northern California, combined with health record data on psychiatric diagnoses, HIV diagnosis, treatment, and control (HIV RNA, CD4), insurance, and neighborhood deprivation index (NDI) to examine factors associated with SI (PHQ-9 item 9 score > 0). Adjusted odds ratios (aOR) for SI were obtained from logistic regression models.
RESULTS RESULTS
Among 2829 PWH screened (92 % male; 56 % white; mean (SD) age of 54 (13) years; 220 (8 %) reported SI. Compared with no problematic use, SI was higher among those reporting one (aOR = 1.65, 95 % CI = 1.17, 2.33), two (aOR = 2.23, 95 % CI = 1.42, 3.49), or ≥ 3 substances (aOR = 4.49, 95 % CI = 2.41, 8.39). SI risk was higher for those with stimulant use (aOR = 3.55, 95 % CI = 2.25, 5.59), depression (aOR = 4.18, 95 % CI = 3.04, 5.74), and anxiety diagnoses (aOR = 1.67, 95 % CI = 1.19, 2.34), or Medicaid (aOR = 2.11, 95%CI = 1.24, 3.60) compared with commercial/other insurance. SI was not associated with HIV-related measures or NDI.
LIMITATIONS CONCLUSIONS
SI was assessed with a single PHQ-9 item. Simultaneous SI and exposure data collection restricts the ability to establish substance use as a risk factor.
CONCLUSIONS CONCLUSIONS
HIV care providers should consider multiple substance use, stimulant use, depression or anxiety, and public insurance as risk factors for SI and provide interventions when needed.

Identifiants

pubmed: 38723683
pii: S0165-0327(24)00755-9
doi: 10.1016/j.jad.2024.05.036
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors report no competing of interest.

Auteurs

Derek D Satre (DD)

University of California, San Francisco, Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, San Francisco, CA 94107, United States of America; Kaiser Permanente Northern California, Division of Research, Pleasanton, CA 94588, United States of America. Electronic address: derek.satre@ucsf.edu.

Varada Sarovar (V)

Kaiser Permanente Northern California, Division of Research, Pleasanton, CA 94588, United States of America.

Tory Levine (T)

Kaiser Permanente Northern California, Division of Research, Pleasanton, CA 94588, United States of America.

Amy S Leibowitz (AS)

Kaiser Permanente Northern California, Division of Research, Pleasanton, CA 94588, United States of America.

Alexandra N Lea (AN)

Kaiser Permanente Northern California, Division of Research, Pleasanton, CA 94588, United States of America.

Kathryn Ridout (K)

Kaiser Permanente Northern California, Division of Research, Pleasanton, CA 94588, United States of America.

C Bradley Hare (CB)

Kaiser Permanente Northern California, Division of Research, Pleasanton, CA 94588, United States of America.

Mitchell N Luu (MN)

Kaiser Permanente Northern California, Division of Research, Pleasanton, CA 94588, United States of America.

Jason Flamm (J)

Kaiser Permanente Northern California, Division of Research, Pleasanton, CA 94588, United States of America.

James W Dilley (JW)

University of California, San Francisco, Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, San Francisco, CA 94107, United States of America.

Thibaut Davy-Mendez (T)

University of North Carolina at Chapel Hill, Department of Medicine, Division of Infectious Diseases, Chapel Hill, NC 27599, United States of America.

Stacy A Sterling (SA)

University of California, San Francisco, Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, San Francisco, CA 94107, United States of America; Kaiser Permanente Northern California, Division of Research, Pleasanton, CA 94588, United States of America.

Michael J Silverberg (MJ)

Kaiser Permanente Northern California, Division of Research, Pleasanton, CA 94588, United States of America.

Classifications MeSH